UroGen Pharma Ltd. (URGN) Cash Flow Statement

The OCF/NI ratio above 1.0 in most quarters indicates that operating cash outflows are larger than net losses, driven by negative working capital changes, particularly in 2026. This suggests that the company is funding growth through inventory and receivables build-up, which may not be sustainable. Investors should monitor whether working capital normalization will further pressure cash flow.

FCF margin improved from -165% in Q2 2025 to -45.6% in Q2 2026, but the absolute burn remains substantial, reflecting heavy investment in commercialization. The trajectory suggests that while revenue is accelerating, cash flow inflection lags, and the company may require additional capital before achieving self-sustainability.

With CapEx/Revenue below 1% consistently, the business model relies on outsourced manufacturing and existing infrastructure, which is typical for a biotech. This implies that the heavy cash outflows are primarily funding R&D and SG&A, not physical expansion, and that future growth may not require significant capital intensity.

The negative working capital changes in recent quarters suggest that the company is building inventory and extending credit to distributors, which is common during a launch. This may indicate that cash flow will improve as the channel stabilizes, but it also raises the risk of inventory write-downs if demand falters.

The absence of capital returns is consistent with a company in a high-burn phase, prioritizing growth over shareholder distributions. This suggests that management is focused on market penetration, but investors should monitor whether this strategy yields a positive return on invested capital as UGN-102 progresses.